Lornoxicam


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Pain 8-16 mg/day. Max: 24 mg/day. Osteoarthritis; Rheumatoid arthritis 12 mg/day in 2 -3 divided doses, up to 16 mg/day. IV/IM Pain 8 mg 1-2 times/day. Max: 24 mg/day.
Dosage Details
Oral
Pain relief
Adult: 8-16 mg daily. Max: 24 mg daily.

Oral
Osteoarthritis, Rheumatoid arthritis
Adult: 12 mg daily in 2-3 divided doses, up to 16 mg daily if needed.

Parenteral
Pain relief
Adult: 8 mg once or twice daily by IM/IV inj. Max: 24 mg daily.
Contraindications
Patients with peptic ulceration; severe renal impairment; pregnancy and lactation.
Special Precautions
Active infections; asthma; allergic disorders; haemorrhagic disorders; hypertension; impaired renal, hepatic, cardiac function.
Adverse Reactions
Abdominal pain, diarrhoea, dizziness, dyspepsia, nausea, vomiting; headache; haematologic disorders; CNS effects; visual disturbance; tinnitus; nephrotoxicity; fluid retention; photosensitivity; alveolitis; pancreatitis; Stevens-Johnson syndrome; toxic epidermal necrolysis; colitis induction/exacerbation; stomatitis; hypertension, palpitation; insomnia, somnolence.
Drug Interactions
Increased lornoxicam blood conc when given concomitantly with cimetidine.Enhanced effects of anticoagulants, sulfonylureas, methotrexate, ciclosporin, digoxin. Decreased effects of diuretics, ACE inhibitors.
Potentially Fatal: Increased risk of lithium toxicity.
Action
Description: Lornoxicam is an NSAID that is used in musculoskeletal, joint disorders and other painful conditions including postoperative pain. Lornoxicam is a potent inhibitor of both COX-1 and COX-2 enzymes.
Pharmacokinetics:
Absorption: Extensively absorbed from the GI tract. Peak plasma concentration within 1-2 hr (oral) or 25 min (IM).
Distribution: 99% bound to plasma proteins.
Metabolism: Metabolised to its inactive metabolite.
Excretion: Excreted in the faeces (as metabolites) and urine (as unchanged drug). Mean elimination half life of 3-4 hr.
Disclaimer: This information is independently developed by MIMS based on Lornoxicam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in